Genome-wide association studies in pharmacogenomics: untapped potential for translation
-
* Corresponding author: Idris Guessous goq3@cdc.gov
1 Emory University, Rollins School of Public Health Department of Epidemiology, Grace Crum Rollins Building, 1518 Clifton Road, Atlanta, Georgia 30322, USA
2 Office of Public Health Genomics, Centers for Disease Control and Prevention, 4770 Buford Highway Mailstop K-89, Atlanta, GA 30341, USA
Genome Med 2009, 1:46 doi:10.1186/gm46
Published: 28 April 2009Abstract
Despite large public investments in genome-wide association studies of common human diseases, so far, few gene discoveries have led to applications for clinical medicine or public health. Genome-wide association studies in the context of clinical trials of drug safety and efficacy may be quicker to yield clinical applications. Certain methodological concerns, such as selection bias and confounding, may be mitigated when genome-wide association studies are conducted within clinical trials, in which randomization of exposure, prospective evaluation of outcome and careful definition of phenotype are incorporated by design.